Error uploading image.
Redefining Mental Health Through AI & Psychedelic Innovation
A visionary biotechnology company pioneering the convergence of artificial intelligence, psychedelic therapeutics, and immersive wellness to transform mental healthcare globally.
Contact Investor Relations
About us
Hollograf represents a paradigm shift in mental healthcare delivery—a next-generation biotechnology company uniquely positioned at the convergence of four revolutionary domains: personalised AI-powered therapy, groundbreaking psychedelic compounds, transformative wellness retreats, and world-class professional education through the Institute of Psychedelic Medicines (IPM).
Our ambitious mission transcends traditional healthcare boundaries: we are creating the world's first truly integrated ecosystem for precision mental health, where advanced diagnostic capabilities, scientifically validated therapeutic compounds, deeply personalised treatment protocols, educational excellence, and transformative healing experiences seamlessly converge within a unified therapeutic framework that addresses the whole person—mind, body, and spirit.
Hollograf AI
A HIPAA-compliant digital therapeutic engine leveraging biometric, psychometric, and real-time emotional feedback to design dynamic, evolving care protocols for depression, PTSD, addiction, and anxiety disorders.
Hollograf Compounds
A portfolio of proprietary psychedelic therapeutics centred on psilocybin and MDMA analogues, currently in early clinical development phases for FDA submission pathways and regulatory approval.
Hollograf Retreats
Premium healing environments across Portugal, Thailand, and the United States where high-touch psychedelic-assisted therapy is administered by licensed practitioners in optimised therapeutic settings.
Institute of Psychedelic Medicines
A fully accredited education platform training clinicians, researchers, and therapists in the ethical, medical, and spiritual application of psychedelic care, ensuring sustainable global impact.
Together, these integrated pillars form a comprehensive system designed to both treat and fundamentally transform the landscape of mental healthcare. We operate at the intersection of four rapidly expanding sectors—AI healthcare, psychedelic medicine, professional education, and premium wellness—with a holistic, technology-enabled solution supported by proprietary intellectual property and a robust go-to-market strategy.
Financial Opportunity
In the next five years, Hollograf is projected to generate over $380M in annual revenue across its complementary verticals, representing exceptional growth potential in an underserved market experiencing unprecedented demand.
We are raising $15M in exchange for 22.5% equity in our Delaware C-Corporation to complete clinical validation and regulatory approvals, launch luxury retreat centres in strategic geographies, and scale the AI platform whilst licensing our therapeutic compounds globally.
The Problem: A Broken Mental Health System
Mental health has emerged as one of the defining challenges of our time, affecting individuals, families, and communities across every demographic and geography. More than 1 billion people globally suffer from anxiety, depression, post-traumatic stress disorder, and trauma-related disorders—a staggering figure that continues to rise year after year, particularly amongst younger generations.
Traditional treatment modalities—talk therapy, selective serotonin reuptake inhibitors (SSRIs), and institutional clinical settings—offer incremental symptomatic relief at best, not the fundamental transformation that patients desperately need. These approaches treat surface-level symptoms rather than addressing the root neurobiological and psychological sources of mental distress, leaving millions trapped in cycles of partial recovery and relapse.
Limited Efficacy
SSRIs demonstrate only 40-60% response rates, with many patients experiencing no meaningful improvement even after multiple medication trials.
Treatment Resistance
Approximately 30% of depression cases are treatment-resistant, leaving patients with few effective options within conventional psychiatric care.
Access Barriers
Long waiting lists, high costs, and geographical limitations prevent millions from receiving timely, quality mental healthcare when they need it most.
Fragmented Care
Current mental health systems operate in silos, with poor integration between pharmacological, therapeutic, and holistic wellness approaches.
A New Paradigm Emerges
Simultaneously, our collective consciousness is opening to the transformative power of psychedelic medicines. Contemporary neuroscience is finally catching up with what ancient cultures have known for millennia: that in the right setting, with the appropriate compounds and expert guidance, genuine healing—not merely symptom management—becomes possible.
Yet today's efforts remain frustratingly fragmented—rigorous science divorced from spiritual wisdom, wellness practices lacking empirical validation, data-driven approaches that lose sight of human experience and meaning.
Enter Hollograf: A New Paradigm
Our Vision: Transformational Care for a Global Mind
Hollograf integrates cutting-edge psychedelic medicine, AI-powered diagnostic and therapeutic platforms, world-class professional education, and immersive wellness environments into a seamless, scientifically rigorous therapeutic ecosystem. Our mission is to fundamentally reshape the standard of care for mental health globally—transitioning from disjointed, fragmented systems to integrated, personalised experiences that are simultaneously scientific, profound, and deeply human.
We don't merely treat psychiatric disorders or manage symptoms. We empower genuine recovery, facilitate personal renewal, and catalyse lasting transformation that extends far beyond the clinical encounter into every aspect of our patients' lives.
Solution Overview
Hollograf's comprehensive therapeutic ecosystem is built upon three synergistic pillars that work in concert to deliver personalised, transformative mental healthcare at unprecedented scale and efficacy.
AI-Powered Personalised Care
Precision mental health diagnostics and dynamically evolving therapy plans informed by comprehensive biometric monitoring, validated psychometric assessments, real-time behavioural data, and longitudinal outcome tracking.
  • Continuous adaptation to individual response patterns
  • Integration with wearable biosensors and mobile platforms
  • Predictive analytics for treatment optimisation
  • HIPAA and GDPR compliant data architecture
Next-Generation Psychedelic Therapeutics
Proprietary pharmaceutical compounds derived from psilocybin, MDMA, mescaline, and novel alkaloid structures, meticulously designed for enhanced safety profiles, optimal therapeutic potency, and regulatory scalability across international markets.
  • Improved pharmacokinetic properties
  • Enhanced bioavailability and stability
  • Novel receptor binding mechanisms
  • Patent-protected formulations
Luxury Immersive Retreats
Scientifically structured, beautifully designed wellness environments that optimise set, setting, and therapeutic outcomes through expert facilitation, integration support, and evidence-based protocols in stunning natural locations.
  • Licensed medical supervision
  • Comprehensive preparation and integration
  • Trauma-informed care approaches
  • Sustainable, regenerative facility design
Why Now? Market Timing & Momentum
Regulatory Momentum Accelerating
The regulatory landscape for psychedelic therapeutics has transformed dramatically in recent years. The FDA stands on the cusp of approving MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression, representing watershed moments for the field. Meanwhile, ketamine has already established legal precedent as a prescribable psychedelic therapy, creating validated pathways for similar compounds.
$3B+
Capital Investment
Total funding deployed into psychedelic biotech and digital mental health startups since 2021, representing unprecedented investor confidence.
156%
Market Growth
Projected compound annual growth rate (CAGR) for the global psychedelic therapeutics market through 2030.
4
Convergent Sectors
AI healthcare, psychedelic medicine, premium wellness, and professional education markets simultaneously reaching maturity.
The Evolution of AI in Mental Healthcare
Traditional mental health applications have proven inadequate—static questionnaires and generalised interventions fail to capture the dynamic, highly individual nature of psychological distress and recovery. Precision care platforms represent the next evolutionary leap, offering adaptive, personalised therapeutic experiences that learn and evolve alongside each patient's unique healing journey.
"Hollograf is uniquely positioned at the intersection of these converging forces—regulatory approval, technological advancement, and unprecedented market demand—creating a once-in-a-generation opportunity to redefine mental healthcare."
First-Mover Advantage
As regulatory pathways open, early entrants with validated technology and clinical data will capture disproportionate market share and establish brand leadership.
Network Effects
Our integrated platform creates powerful data network effects—each patient interaction improves AI accuracy, benefiting all future patients exponentially.
Infrastructure Gap
Existing mental health systems lack the technological and therapeutic infrastructure to deliver psychedelic-assisted care at scale—we are building that infrastructure.
Technology & Intellectual Property Strategy
Hollograf's technology platform is architected to support scalable, individualised psychedelic mental healthcare delivery across diverse patient populations and clinical settings. The system is powered by proprietary artificial intelligence algorithms and underpinned by an evolving intellectual property strategy meticulously designed to safeguard and commercially exploit both software and biotechnology assets.
AI Platform Architecture
Our adaptive AI engine is trained using rigorously anonymised biometric, psychometric, behavioural, and clinical outcome data aggregated from multiple sources. The platform seamlessly integrates real-time data streams from consumer wearable devices, standardised therapist assessments, validated patient-reported outcome measures, and neurophysiological monitoring equipment to generate dynamically personalised treatment pathways in real-time.
01
Data Integration Layer
Aggregates multi-modal data from wearables, electronic health records, and patient interfaces with standardised formatting.
02
Machine Learning Core
Hybrid architecture combining supervised learning for pattern recognition with reinforcement models optimised for emotional response prediction.
03
Clinical Decision Support
Generates evidence-based treatment recommendations whilst maintaining clinician oversight and therapeutic alliance.
04
Continuous Learning Loop
System performance improves over time through outcome feedback, creating compound value with each patient interaction.
Strategic Partnerships
We are cultivating strategic collaborations with leading wearable device manufacturers including Apple, Oura, and Whoop, as well as premier academic psychiatry departments at institutions such as UCLA, Johns Hopkins, and Imperial College London. These partnerships will dramatically expand our training dataset diversity and enhance predictive accuracy across varied patient populations.
Drug Development Pipeline
1
Psilocin Analogues
Novel formulations with significantly improved bioavailability, extended shelf stability, and enhanced therapeutic window for safer dosing protocols.
2
MDMA & Psilocybin Therapies
Next-generation therapeutic protocols designed to meet stringent global regulatory guidelines with modular dosing structures for personalised treatment.
3
Proprietary Alkaloid Extractions
Compounds derived from underexplored botanical species, specifically targeted toward trauma resolution and addiction treatment applications.
Data Infrastructure & Security
All patient information is securely stored within a blockchain-powered infrastructure that enables immutable audit trails, granular dynamic consent management, and selective de-identification protocols for research collaboration or commercial licensing. Our platform maintains full compliance with HIPAA, GDPR, and emerging psychedelic medicine data-sharing regulatory frameworks.
Data monetisation opportunities will be pursued through carefully structured B2B licensing partnerships with academic research institutions, pharmaceutical corporations, and digital health technology companies, creating significant additional revenue streams whilst advancing scientific understanding.
Clinical Development Strategy
Hollograf's clinical development roadmap is meticulously structured to satisfy both FDA and European Medicines Agency (EMA) regulatory requirements whilst strategically leveraging established regulatory precedents from ketamine and MDMA psychedelic therapy programmes. Our comprehensive strategy emphasises early validation, rapid-cycle iteration based on interim data, and cross-jurisdictional regulatory alignment to accelerate market access.
Phase I: Feasibility & Safety (2025)
Study Design: Open-label, non-randomised pilot studies conducted at retreat facilities in Portugal and Thailand.
Investigational Compounds: Psilocybin and MDMA-based therapeutic protocols with standardised preparation and integration.
Sample Size: 60 participants enrolled across 2 international retreat sites with comprehensive longitudinal follow-up.
Primary Endpoints: Safety profile, tolerability assessment, successful biometric and psychometric data integration with AI therapeutic platform.
Regulatory Status: IRB-approved protocols. Patient enrolment commencing Q3 2025.
Phase II: Efficacy & AI Refinement (2026)
Study Design: Double-blind, placebo-controlled randomised trials with multi-arm dosing comparison groups.
Clinical Sites: Multi-site international study spanning United States, Thailand, and Portugal facilities.
Sample Size: 240 participants with balanced demographic representation and diagnosis stratification.
Primary Endpoints: Montgomery-Åsberg Depression Rating Scale (MADRS), Quick Inventory of Depressive Symptomatology (QIDS-SR16), Clinician-Administered PTSD Scale (CAPS-5), AI-informed symptom trajectory prediction accuracy validation.
Key Milestone: Interim data readout and independent Data Safety Monitoring Board review scheduled Q2 2026.
Phase III: Pivotal Registration Trials (2027)
Study Design: Large-scale, multicentre international pivotal studies co-developed in consultation with FDA Breakthrough Therapy Designation guidelines and EMA regulatory framework.
Sample Size: 400-600 participants across North American, European, and Asia-Pacific clinical sites.
Target Indications: Major depressive disorder (MDD), post-traumatic stress disorder (PTSD), treatment-resistant generalised anxiety disorder (GAD).
Statistical Power: Designed for regulatory approval with >90% power to detect clinically meaningful treatment effects.
Regulatory Milestones & Timeline
This comprehensive, risk-mitigated approach ensures robust clinical validation across diverse patient populations, operational scalability for commercial deployment, and expedited regulatory pathways for both AI-enabled digital therapeutics and novel psychedelic pharmaceutical compounds. Our dual-track regulatory strategy maximises the probability of successful market authorisation whilst maintaining scientific rigour and patient safety as paramount priorities.
Business Model & Revenue Streams
Hollograf's diversified revenue architecture creates multiple reinforcing income streams across complementary verticals, reducing concentration risk whilst maximising total addressable market capture. Each revenue channel targets distinct customer segments with tailored value propositions and pricing models optimised for that market.
Revenue Synergies & Network Effects
These revenue streams create powerful synergistic effects. Retreat clients generate valuable clinical data that improves AI platform accuracy. Educated clinicians through IPM become distribution channels for our SaaS platform. Corporate wellness contracts provide stable recurring revenue whilst building brand credibility. Pharmaceutical licensing partnerships validate our compound IP and accelerate regulatory pathways.
Retreats
Premium positioning with 45-60% gross margins and strong word-of-mouth referrals.
AI SaaS
Highly scalable with 85%+ gross margins and exponentially growing data moat.
Compound IP
Passive income with minimal marginal costs and 20+ year patent protection.
Data Assets
Continuously appreciating asset that becomes more valuable with scale.
B2B Wellness
Stable enterprise contracts with predictable renewal rates and expansion revenue.
IPM Education
Brand building and thought leadership whilst generating early cash flow.
Traction & Validation
Hollograf has achieved significant early-stage validation across technology development, clinical proof-of-concept, strategic partnerships, and team assembly—de-risking subsequent scale-up phases and demonstrating executable progress toward our ambitious vision.
Technology Development Milestones
Our engineering team has successfully completed development of the alpha version of our AI diagnostic and therapeutic recommendation engine. This functional prototype has undergone rigorous testing with 150 volunteer subjects across diverse demographic groups, yielding preliminary validation of our core algorithmic approaches and user interface design.
Early results demonstrate promising accuracy in mood state classification (82% concordance with clinician assessments) and treatment response prediction (72% sensitivity for identifying optimal therapeutic modalities). These initial performance metrics provide strong foundation for subsequent refinement and regulatory validation studies.
Academic Partnerships
Active collaborative discussions underway with UCLA Department of Psychiatry and Biobehavioural Sciences and Chiang Mai University Faculty of Medicine regarding joint research protocols, clinical trial site agreements, and data sharing frameworks.
World-Class Advisory Board
Assembled exceptional advisory board including leading researchers and clinicians from Johns Hopkins Center for Psychedelic and Consciousness Research, MIT Media Lab, and Multidisciplinary Association for Psychedelic Studies (MAPS).
IRB Approval
Obtaine Institutional Review Board approvals for Phase I safety and feasibility studies at Thailand retreat facilities, enabling patient enrolment to commence Q2 2026 as planned.
Provisional Patents Filed
Filed provisional patent applications covering our AI therapeutic algorithms, novel compound formulations, and data integration methodologies—establishing priority dates and creating defensible IP moat.
Early Market Signals
Soft-launch marketing efforts for the Institute of Psychedelic Medicines have generated a waiting list of over 400 healthcare professionals interested in certification programmes, validating strong demand for professional education in this emerging field. Additionally, preliminary discussions with three Fortune 500 corporations regarding pilot corporate wellness programmes demonstrate B2B market receptivity.
Go-to-Market Strategy
Our phased market entry strategy balances aggressive growth ambitions with prudent risk management, sequencing revenue stream activation to build credibility, generate early cash flow, and create compounding network effects that accelerate subsequent expansion.
Phase 1: Foundation (2025)
Launch Institute of Psychedelic Medicines to establish thought leadership and educational brand authority. Execute targeted community building through speaking engagements at major conferences (SXSW, Milken Institute, Psychedelic Science). Cultivate strategic partnerships with academic institutions and professional associations. Generate early revenue whilst building brand equity and distribution network of educated clinicians.
Phase 2: Commercial Launch (2026)
Open flagship retreat locations in Portugal and Thailand, targeting affluent early adopters and influential tastemakers. Initiate SaaS platform pilot programme with carefully selected integrative therapists and progressive mental health clinics (target: 50 pilot partners). Generate clinical outcome data to support AI refinement and pharmaceutical regulatory submissions. Establish proof-of-concept for revenue model across multiple streams.
Phase 3: Scale & Expansion (2027+)
Execute global scale-up strategy with additional retreat locations and expanded SaaS distribution. Activate cross-licensing agreements for pharmaceutical compounds with major pharma partners. Achieve full commercial availability of AI platform across healthcare systems. Target enterprise B2B channel through corporate wellness programmes. International expansion into European and Asia-Pacific markets with localised offerings.
Distribution Channels & Customer Acquisition
B2C Channels
  • Scientific and medical conferences with targeted audience
  • Key opinion leader (KOL) physician networks and referrals
  • Premium medical tourism platforms and concierge services
  • Content marketing and thought leadership publications
  • Strategic partnerships with complementary wellness brands
B2B Channels
  • Direct enterprise sales to Fortune 500 HR/benefits teams
  • Health system partnerships and value-based care contracts
  • Pharma R&D collaborations and licensing agreements
  • Academic research institution partnerships
  • Professional association and certification body relationships
Customer acquisition cost (CAC) is projected to decline from $2,500 in Year 1 to $800 by Year 5 as brand recognition strengthens, word-of-mouth referrals increase, and digital acquisition channels mature. Lifetime value (LTV) expands from $12,000 to $25,000 over the same period through repeat purchases, subscription renewals, and cross-selling across our vertically integrated service portfolio.
Leadership Team
Hollograf is led by an exceptional founding team combining deep expertise across biotechnology, psychiatry, artificial intelligence, operations, and finance. Our complementary skill sets and shared vision create a formidable foundation for executing our ambitious growth strategy.
Dr. Chris Corney
Co-Founder & CEO
Brings extensive clinical psychiatry experience and deep understanding of psychedelic therapeutics. Responsible for clinical strategy, medical operations, regulatory affairs, and overall company vision. Published researcher with expertise spanning neuropharmacology, trauma treatment, and integrative mental healthcare approaches.
Dr. Mitch McKean
Chief Medical Officer
A highly respected medical professional with deep expertise in psychedelic-assisted therapy development and clinical trials. Dr. McKean will lead the integration of medical science into Hollograf's product development, ensuring clinical rigor, patient safety, and adherence to evolving regulatory standards in psychedelic medicine.
Gary Mackenzie
Founder, Corporate Strategy & Capital
Seasoned entrepreneur with track record of successful exits and strategic capital raising. Leads corporate development, investor relations, strategic partnerships, and M&A activities. Brings extensive network across biotech venture capital, pharmaceutical corporations, and institutional investors.
Luke Mackenzie
Founder, Operations & Analytics
Technical operations expert with specialisation in data systems architecture and business analytics. Oversees technology infrastructure, data science team, blockchain implementation, and operational efficiency initiatives. Previously led data engineering teams at high-growth technology companies.
Scientific Advisory Board
Hollograf benefits from guidance and expertise of world-renowned advisors from leading institutions including Johns Hopkins Center for Psychedelic and Consciousness Research, Compass Pathways, Multidisciplinary Association for Psychedelic Studies (MAPS), Imperial College London Centre for Psychedelic Research, and the European Medicines Agency. This exceptional advisory network provides scientific credibility, regulatory guidance, and access to cutting-edge research findings.
U.S. Chief Operating Officer Search
To support our United States market expansion and operational excellence, we are actively recruiting a highly qualified U.S.-based Chief Operating Officer with dual expertise in clinical psychiatry and healthcare business strategy. Target candidate profile includes:
  • Medical degree in psychiatry (MD or DO) from accredited U.S. institution
  • MBA from top-tier business school with healthcare management focus
  • Proven experience scaling digital health or biotechnology companies within the complex U.S. regulatory and commercial landscape
  • Established network across U.S. healthcare systems, payers, and psychiatric institutions
This strategic hire will dramatically accelerate institutional credibility, clinical network partnerships, and operational readiness for U.S.-based psychedelic-assisted therapy rollouts commencing in 2026.
Environmental, Social & Governance (ESG) Commitment
Hollograf is committed to building a regenerative, ethical, and socially impactful enterprise from inception. Our operational model aligns closely with several United Nations Sustainable Development Goals (SDGs) and incorporates rigorous ESG principles across health access, professional education, community resilience, environmental stewardship, and ethical governance.
SDG 3: Good Health & Wellbeing
All therapeutic interventions are rigorously evidence-based, with clinical outcomes systematically tracked via our AI platform using internationally validated assessment instruments including MADRS, QIDS, PCL-5, and GAD-7. Our ambitious goal is to measurably improve mental health outcomes for at least 100,000 individuals globally by 2030, with transparent reporting of effectiveness data and continuous quality improvement protocols.
SDG 4: Quality Education
Through the Institute of Psychedelic Medicines, we aim to certify more than 1,000 mental health professionals across diverse geographies within five years, with measurable positive impacts on global access to qualified, ethical psychedelic-assisted care. Our curriculum emphasises cultural competency, trauma-informed approaches, and evidence-based practice standards.
SDG 8: Decent Work & Economic Growth
We are creating sustainable, high-quality employment opportunities in biotechnology, clinical therapy, technology development, and wellness services across four countries. Our commitment includes ethical labour standards, competitive compensation, professional development pathways, and prioritisation of local hiring within retreat communities to stimulate regional economic development.
Environmental Sustainability
All Hollograf retreat facilities are being constructed using low-carbon, regenerative building materials including hempcrete, reclaimed timber, and non-toxic finishes. Facilities incorporate solar microgrids, rainwater harvesting systems, greywater recycling, and regenerative landscaping principles. We are targeting LEED Platinum or Living Building Challenge certification for all permanent structures.
Operational protocols minimise waste generation, eliminate single-use plastics, source organic local food, and offset remaining carbon emissions through verified reforestation programmes.
Ethical Data Governance
Patient data privacy and security represent paramount priorities. All personally identifiable information is managed under strict HIPAA and GDPR regulatory requirements, with blockchain-based granular consent management and military-grade encryption protocols. We are actively exploring engagement with third-party data ethics auditors to provide independent verification of our practices commencing in 2026.
Our data monetisation model incorporates explicit patient consent, transparent benefit-sharing mechanisms, and independent ethics board oversight to ensure participant interests remain protected whilst advancing scientific knowledge.
Impact Measurement & Transparency
Impact metrics across all ESG dimensions will be rigorously tracked using quantitative key performance indicators and externally validated methodologies. We commit to publishing comprehensive annual stakeholder impact reports beginning FY2026, providing transparent disclosure of progress, challenges, and areas requiring improvement across our sustainability and social impact objectives.
Legal Disclaimer

Important Investment Disclosure
This business plan document is intended solely for informational purposes and is provided exclusively to qualified, accredited investors who have been specifically invited to review this opportunity. This document does not constitute an offer to sell or a solicitation of an offer to purchase securities in any jurisdiction where such offer or solicitation would be unlawful.
Forward-looking statements contained herein, including projections of revenue, profitability, market adoption, regulatory approvals, and strategic milestones, reflect the current views and assumptions of the company's founders and management team at the time of writing. Such statements are subject to numerous risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied.
Investment in early-stage biotechnology, digital health, and psychedelic therapeutics ventures involves substantial financial risk and may result in partial or total loss of invested capital. Past performance of similar companies or investments is not indicative of future results. Prospective investors should conduct their own independent due diligence, consult with financial, legal, and tax advisors, and carefully consider their risk tolerance and investment objectives before making any investment decision.
No representation or warranty, express or implied, is made as to the accuracy, completeness, or fairness of the information contained in this document. Neither the company nor its affiliates, advisors, or representatives shall have any liability for any loss or damage arising from use of this information.
Any investment will be subject to definitive legal documentation including subscription agreements, shareholders' agreements, and disclosure schedules that will supersede any information contained herein.
Error uploading image.
Contact Hollograf
Investor Relations
For confidential investment enquiries, partnership opportunities, or additional information about Hollograf's vision and growth strategy, please contact our dedicated investor relations team.
Email: ​gary@gdmventures.asia ​
Social Media: @Hollograflabs
We welcome engagement with accredited investors, strategic partners, and individuals who share our vision of transforming mental healthcare through the integration of cutting-edge technology, validated psychedelic therapeutics, and compassionate, personalised care.
Hollograf® is a registered trademark. All rights reserved. © 2025 Hollograf Inc.